At a glance
- Originator Bayer Schering Pharma
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Contraception
Most Recent Events
- 08 Dec 1998 No-Development-Reported for Contraception in Germany (PO)
- 17 Jan 1997 New profile
- 17 Jan 1997 Phase-I clinical trials for Contraception in Germany (PO)